Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug consisting of **pseudoephedrine**, **chlorpheniramine**, and **belladonna alkaloids**. - **Pseudoephedrine** is a sympathomimetic amine that acts as an alpha and beta adrenergic receptor agonist, leading to vasoconstriction and decongestion of nasal passages. - **Chlorpheniramine** is a first-generation antihistamine that acts as an antagonist at H1 histamine receptors, reducing the symptoms of allergies such as sneezing, itching, and runny nose. - **Belladonna alkaloids** are antimuscarinic agents (typically including atropine, hyoscyamine, and scopolamine) that produce anticholinergic effects such as reduction in glandular secretions, relaxation of smooth muscles, and antispasmodic actions. This combination is generally intended for symptomatic relief in upper respiratory conditions such as the **common cold**, **allergic rhinitis**, and related conditions where decongestion, antihistaminic, and antispasmodic effects are beneficial[2][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pseudoephedrine + chlorpheniramine + belladonna alkaloids.